Navigation Links
Ben-Gurion University of the Negev professor awarded the 2010 Elkeles Prize for Cancer Research
Date:8/8/2010

BEER-SHEVA, ISRAEL, August 9, 2010 Ben-Gurion University of the Negev (BGU) Professor Ron N. Apte has been awarded the 2010 Samuel and Paula Elkeles Prize for Outstanding Scientist in the Field of Medicine.

Professor Apte is chairman of the Shraga Segal Department of Microbiology and Immunology and vice dean of the Basic Sciences division in the BGU Faculty of Health Sciences. He is also the Irving Sklar Chair in Endocrinology and Cancer and a member of the National Institute for Biotechnology in the Negev.

Apte's major field of research involves inflammation in malignant processes. Approximately 15 percent of cancers are connected to inflammation, which typically result in organs where chronic inflammation has occurred. For example, patients with Inflammatory Bowel Disease (IBD) are more prone to cancer than the general population.

The pioneering studies of Apte's group demonstrated the feasibility of intervening in malignant process by neutralizing inflammatory components in the "normal" microenvironment of a tumor. They also detailed the basic concepts underlying such treatment.

Inflammatory cells affect proliferation and invasiveness of malignant cells through the secretion of cytokines, which include Interleukin-1 (IL-1), the molecule that has been studied for years by Apte's group. The group has demonstrated the involvement of IL-1-mediated inflammation in tumor invasiveness and metastasis. IL-1 causes tumor expansion because it suppresses the immune system and nourishes a tumor's blood vessels. Apte's group treated tumor-bearing mice with a specific inhibitor of IL-1, known as the IL-1 receptor antagonist (IL-Ra), and succeeded in weakening the tumor's invasiveness.

IL-Ra, in its generic form Anakirna, is a medication that efficiently alleviates symptoms of patients suffering from rheumatoid arthritis, a chronic inflammatory disease.

Apte joined the BGU Faculty of Sciences in 1981 and has served two full terms as vice dean, as the vice dean of Student Affairs, and as the vice dean for Graduate Studies. Since 2008, he has been the vice dean for Basic Science Affairs.

Apte has been a member of the board of the European Cytokine Society since 1989 and has served on the board of its journal, "The European Cytokine Network". He was also president of the Israel Immunological Society from 1996 to 1998.

Apte has served as a charter member of the International Cancer Microenvironment Society (ICMS) and as an editorial board member of its journal "Cancer Microenvironment". Prof. Apte has published more than 80 papers in the fields of immunology, tumor biology and cytokine biology.


'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-353-2505
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Related biology news :

1. Ben-Gurion University of the Negev researchers identify risks of hypertension in young adults
2. FDA approves trial for type 1 diabetes treatment by Ben-Gurion U. and U. Colorado
3. Ben-Gurion U researchers isolate microalgal strain that could reduce cholesterol
4. Uniform method to interpret autism spectrum disorders is defined at Ben-Gurion University
5. Anti-inflammatory drugs (coxibs) interfere with aspirins clotting ability -- Ben-Gurion U.
6. Heartburn drugs deemed safe for fetuses according to Ben-Gurion University researchers
7. Ben-Gurion University Alzheimers researcher demonstrates specific immune response to vaccine
8. Ben-Gurion University of the Negev technology being developed for use in Jordan desalination plant
9. Ben-Gurion U. developing new computer techniques to analyze historic Hebrew and Arabic documents
10. 1 in 6 health workers wont report in flu pandemic -- study by Ben-Gurion U. researchers
11. Ben-Gurion U. researchers reveal connection between cancer and human evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016   Avanade ... successful Formula One teams in history, exploit biometric data ... stop performance and maintain the competitive edge against their ... 2016. Avanade has worked with Williams ... range of biometric data (heart rate, breathing rate, temperature ...
(Date:12/6/2016)... RALEIGH, N.C. , Dec. 6, 2016 ... technology, announced today it has seen a third consecutive ... biometric sensor technology in 2016 with a 360 ... over last year. This increase was driven by sales ... well as robust interest in its technology for hearables ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse® IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
(Date:12/8/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... 2 diabetes, announced that it has obtained a ... vector developed in the laboratory of Professor ... The company plans to use this vector in ... "Early research has shown promise ...
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... commercial launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal ... extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture ...
Breaking Biology Technology: